What question did this study set out to answer?

The study aims to explore whether canagliflozin offers cardioprotective effects against myocardial ischemia/reperfusion injury in both diabetic and nondiabetic models.

January 30, 2019JACC Basic to Translational ScienceOpen Access

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart

View Full Paper

Ask AI

Bookmark

Authors

VLVen Gee LimUniversity Hospital Coventry RBRobert M. BellUniversity of British Columbia SASapna ArjunWilliam Harvey Research Institute

Discussion

Member takes

Implication

Randomized trial shows that canagliflozin reduces myocardial infarction in diabetic and nondiabetic hearts, suggesting new treatment options.

Key Points

The study aims to explore whether canagliflozin offers cardioprotective effects against myocardial ischemia/reperfusion injury in both diabetic and nondiabetic models.
Langendorff-perfused hearts from diabetic and nondiabetic rats were treated with canagliflozin for 4 weeks.
Infarct sizes were compared between treated and untreated groups of rats.
Direct treatment of isolated nondiabetic hearts with canagliflozin was also performed to assess its effect on infarct size.
Canagliflozin treatment significantly reduced infarct sizes in both diabetic and nondiabetic rats compared to control.
Isolated nondiabetic heart treatment with canagliflozin showed no effect on infarct size, indicating the necessity of long-term treatment.
Findings suggest a glucose-independent cardioprotective mechanism or activation of prosurvival pathways in the heart.

Cite This Study

Lim et al. (2019) studied this question.

synapsesocial.com/papers/6a33643b5d2f1ecbcf8b1bc5 https://doi.org/10.1016/j.jacbts.2018.10.002

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows that canagliflozin reduces myocardial infarction in diabetic and nondiabetic hearts, suggesting new treatment options.

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart

Discussion

Member takes

Implication

Key Points

Cite This Study

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider